May 13, 2013
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in
South East Asia
This collaboration is a part of NanoPass's long-term commitment to improve Global Health by providing access to its vaccine delivery devices.
The study is a phase 3, open-label, randomized clinical trial comparing immune response after receiving one of five different combinations of polio vaccines delivered as oral drops or as injections into the muscle or the skin. Two of the vaccine regimens include a low (20%) dose vaccine delivered intradermally using the MicronJet device. The study is currently enrolling infants 6 weeks of age and aims to enroll over 1,200 participants.
In the pre-vaccine era, poliomyelitis was the leading cause of permanent disability. Two polio
are used throughout the world to combat
(or polio); injected inactivated
(IPV) and live attenuated oral vaccine. IPV administration is needed globally to achieve polio eradication, but it is currently unaffordable for most of the developing world. Intradermal delivery may dramatically reduce the dose required for vaccination by several folds, thereby reducing the cost and increasing the affordability, of polio vaccines.
, CEO of NanoPass, said, "We are delighted to support CDC as part of NanoPass's long term commitment to Global Health. We see an important opportunity for significantly reducing the dose of vaccination and hence its cost, by combining our device approach with polio vaccines. We will continue to provide access to our technology to public and private vaccine developers for Global Health applications, as we have to date with some of our partners including the Infectious Disease Research Institute (IDRI.org). The MicronJet600 device is the shortest microneedle device presently registered with FDA, and since it is about half a millimeter long it is applicable for infants as well as adults.
NanoPass is involved in another Polio study in 231 HIV positive adults. The study is sponsored by the
Eastern Virginia Medical School
and aims to determine whether a lower dose of inactivated polio vaccine (IPV) injected ID can work equally well or better than the standard dose injected into the muscle. The study is enrolling participants infected with HIV because they are known to respond less well to vaccines than other groups.
NanoPass has also supported a pandemic flu phase I study sponsored by IDRI and Medicago, which investigated multiple strategies including intradermal delivery to improve immune responses and reduce doses for vaccination for the H5 pandemic flu vaccine.